MGC Pharmaceuticals' Malta facility has received formal EU-Good Manufacturing Practice (GMP) certification, enabling the production of high-quality plant-inspired medicines such as CannEpil and CimetrA. The large-scale facility can produce over 20
Charles Collins-Chase, partner, and Harry Muttock, associate, at international IP law firm, Finnegan, explore AI’s potential and how companies can use IP to protect their investments in AI technology.
EPM spoke with Nick Porter and Simon Brinckmann, World Courier, about its investment in a real-time location monitoring solution, the unique logistics considerations posed by ATMPs, and World Courier’s expanding geographic footprint.
Kai Lipinski, PhD, chief scientific officer of Vibalogics, a Recipharm company, focuses on oncolytic viruses (OVs); explaining how early-stage drug developers can overcome the challenges in scaling up and commercialising their products.
Erica Cohen, Greenphire, and Thomas Smith, LS public engagement specialist, explore the current issues that hinder rare disease clinical trials, and what solutions should be invested and incorporated to maximise flexibility for the trial patients.
EntityRisk announced that Jeffrey B. Kindler and Frank D’Amelio have led a Series A investment in the company and have been appointed to EntityRisk’s board of directors.
Prof. Andy Whiting, Nevrargenics, responds to the lack of translational funding for the biotech industry, and what more needs to be done to close the gap between drug development and clinical trials.
Michael Franco, director, global biopharma sales at PSG Biotech, highlights the pain points that must be overcome in critical life science procedures and biopharmaceutical production operations.
Ahead of CPHI Japan 2023, Ian Haydock, Citeline, predicts that the continued rise of biopharma innovation in China is the big macro trend in the APAC region that could potentially lead to shifts in outsourcing and manufacturing strategies regionally.
